Related articles:

Emergent BioSolutions Inc.: Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 24, 2018 at 9:00 AM EDT; Webcast Will Be Available
May 10, 2018

Emergent BioSolutions Inc.: Emergent BioSolutions Reports First Quarter 2018 Financial Results
May 03, 2018

Emergent BioSolutions Inc.: Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018
April 19, 2018

Emergent BioSolutions Inc.: Emergent BioSolutions Announces Preliminary 2017 Financial Results and Provides 2018 Financial Outlook
January 08, 2018

Emergent BioSolutions Inc.: Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection
January 04, 2018

Emergent BioSolutions Inc.: Emergent BioSolutions to Participate in First Quarter 2018 Investor Conferences
January 03, 2018

Emergent BioSolutions Inc.: Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility
November 20, 2017

Emergent BioSolutions Inc.: Emergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Senior Notes Due 2021
November 14, 2017

Emergent BioSolutions Inc.: Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance
November 02, 2017

Emergent BioSolutions Inc.: Emergent BioSolutions to Release Third Quarter and Nine Months 2017 Financial Results and Conduct a Conference Call on November 2, 2017
October 19, 2017

Emergent BioSolutions Inc.: Emergent BioSolutions Completes Acquisition of ACAM2000® Business From Sanofi
October 06, 2017

Emergent BioSolutions Inc.: Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
October 03, 2017

Emergent BioSolutions Inc.: Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance
August 03, 2017

Emergent BioSolutions Inc.: Emergent BioSolutions to Release Second Quarter 2017 Financial Results and Conduct a Conference Call on August 3, 2017
July 20, 2017

Emergent BioSolutions Inc.: Emergent BioSolutions to Acquire Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
July 19, 2017

Emergent BioSolutions Inc.: Emergent BioSolutions to Acquire ACAM2000® Business From Sanofi
July 14, 2017

Emergent BioSolutions Inc.: Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 25, 2017 at 9:00 AM EDT; Webcast Will be Available
May 11, 2017

Emergent BioSolutions Inc.: Emergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance
May 04, 2017

Emergent BioSolutions Inc.: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2016 Financial Results; Reaffirms 2017 Guidance and Provides 2020 Goals
February 23, 2017

Emergent BioSolutions Inc.: Emergent BioSolutions to Release Fourth Quarter and Full Year 2016 Financial Results and Conduct a Conference Call on February 23, 2017
February 09, 2017

Emergent BioSolutions Inc.: Emergent BioSolutions Announces Preliminary 2016 Financial Results and Provides 2017 Financial Outlook
January 09, 2017

Emergent BioSolutions Inc.: Emergent BioSolutions to Participate in First Quarter 2017 Investor Conferences
December 29, 2016

Emergent BioSolutions Inc.: Emergent BioSolutions Reports Second Quarter and Six Months 2016 Financial Results
August 04, 2016

Emergent BioSolutions Inc.: Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics
August 01, 2016

Emergent BioSolutions Inc.: Emergent BioSolutions’ Board of Directors Approves Spin-Off of Aptevo Therapeutics and Sets Record and Dividend Distribution Dates and Distribution Ratio
July 11, 2016

Emergent BioSolutions Inc.: Emergent BioSolutions to Release First Quarter 2016 Financial Results and Conduct a Conference Call on May 5, 2016
April 21, 2016

Emergent BioSolutions Inc.: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2015 Financial Results and Reaffirms 2016 Outlook
February 25, 2016

Emergent BioSolutions Inc.: Emergent BioSolutions to Release Fourth Quarter and Full Year 2015 Financial Results and Conduct a Conference Call on February 25, 2016
February 11, 2016

Emergent BioSolutions Inc.: Emergent Biosolutions Announces Preliminary 2015 Financial Results, Provides 2016 Financial Outlook, and Outlines New Five-Year (2016-2020) Strategic Growth Plan
January 11, 2016

Emergent BioSolutions Inc.: Emergent BioSolutions Announces Composition of Board of Directors of New Spin-Off Company Aptevo Therapeutics
December 22, 2015

Emergent BioSolutions Inc.: Emergent BioSolutions to Participate in First Quarter 2016 Investor Conferences
December 21, 2015

Emergent BioSolutions Inc.: Emergent BioSolutions Announces Plan to Implement Tax-Free Spin-Off of Biosciences Business Into a Separate Publicly-Traded Company
August 06, 2015

Emergent BioSolutions Inc.: Emergent BioSolutions to Release Second Quarter 2015 Financial Results and Conduct a Conference Call on August 6, 2015
July 23, 2015

Emergent BioSolutions Inc.: Emergent BioSolutions Signs Long-Term Manufacturing Agreement With Prometic Life Sciences
May 19, 2015

Emergent BioSolutions Inc.: Emergent BioSolutions Reports First Quarter 2015 Financial Results
May 07, 2015

Emergent BioSolutions Inc.: Emergent BioSolutions Completes Investigation and Resumes BioThrax Manufacturing Activities; Re-Affirms Previous Full-Year 2015 Financial Outlook
April 22, 2015

Emergent BioSolutions Inc.: Emergent BioSolutions Signs Agreements With Oxford University, GlaxoSmithKline, and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate
March 16, 2015

Emergent BioSolutions Inc.: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2014 Financial Results and Provides Update on 2015 Outlook
March 05, 2015

Emergent BioSolutions Inc.: Emergent BioSolutions Announces Preliminary 2014 Financial Results and Provides 2015 Financial Outlook
January 11, 2015

Emergent BioSolutions Inc.: Emergent BioSolutions Expands Biodefense Franchise; Acquires Portfolio of Broad Spectrum Antibiotics
December 17, 2014

Emergent BioSolutions Inc.: Emergent BioSolutions Reports Third Quarter and Nine Month 2014 Financial Results
November 06, 2014

Emergent BioSolutions Inc.: Emergent BioSolutions and MorphoSys Sign License Agreement to Co-Develop and Commercialize Prostate Cancer Drug Candidate ES414
August 19, 2014

Emergent BioSolutions Inc.: Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2014
August 07, 2014

Emergent BioSolutions Inc.: Emergent BioSolutions to Release Second Quarter 2014 Financial Results and Conduct a Conference Call on August 7, 2014
July 10, 2014

Emergent BioSolutions Inc.: Emergent BioSolutions Reports First Quarter 2014 Financial Results
May 08, 2014

Emergent BioSolutions Inc.: Emergent BioSolutions to Release First Quarter 2014 Financial Results and Conduct a Conference Call on May 8, 2014
April 23, 2014

Emergent BioSolutions Inc.: Emergent BioSolutions Reports Financial Results for 2013
March 06, 2014

Emergent BioSolutions Inc.: Emergent BioSolutions to Release Fourth Quarter and Full Year 2013 Financial Results and Conduct a Conference Call on March 6, 2014
March 03, 2014

Emergent BioSolutions Inc.: Emergent BioSolutions Completes Acquisition of Cangene Corporation
February 21, 2014

Emergent BioSolutions Inc.: Emergent BioSolutions Announces Completion of $250 Million Convertible Senior Notes Offering
January 29, 2014